CA3256935A1 — Oral liquid suspension of pan-raf kinase inhibitor
Assigned to Day One Biopharmaceuticals Inc · Expires 2023-11-23 · 2y expired
What this patent protects
Disclosed herein are solid formulations of (R)-2-(l-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (Compound A) or a pharmaceutically acceptable salt thereof for preparing liquid suspensions. In another aspect, …
USPTO Abstract
Disclosed herein are solid formulations of (R)-2-(l-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (Compound A) or a pharmaceutically acceptable salt thereof for preparing liquid suspensions. In another aspect, the instant application provides methods of preparation of liquid suspensions and kits of solid formulations comprising Compound A. In another aspect, the instant application provides methods of treating cancer with formulations of Compound A. Additionally, the instant disclosure provides methods of treating pediatric cancer patients by the administration of formulations of Compound A.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.